Incyte executive sells 10,803 shares in planned trade

Incyte Corp reported that President, Global Head of R&D Pablo J. Cagnoni sold 10,803 shares of common stock on 2026-08-12 at $120.04 per share in an open-market transaction under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Incyte Corp reported that President, Global Head of R&D Pablo J. Cagnoni sold 10,803 shares of common stock on 2026-08-12 at $120.04 per share in an open-market transaction under a Rule 10b5-1 trading plan. Following this sale, he reported 194,001 shares held directly, including 183,200 shares issuable from unvested restricted and performance stock units.

Insider Trade Summary 10b5-1

Net Seller: 10,803 shares

Net Sell 1 txn

Insider CAGNONI PABLO J

Role President, Global Head of R&D

Sold 10,803 shs ($1.30M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	10,803	$120.04	$1.30M

Holdings After Transaction: Common Stock — 194,001 shares (Direct)

Footnotes (1)

1. F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Key Figures

Shares sold: 10,803 shares Sale price: $120.04 per share Shares following transaction: 194,001 shares +2 more

5 metrics

Shares sold 10,803 shares Common stock sale reported on 2026-08-12

Sale price $120.04 per share Price for the 10,803 shares of common stock sold

Shares following transaction 194,001 shares Direct holdings reported after the sale

Unvested equity awards 183,200 shares Shares issuable from unvested RSUs and earned PSUs included in reported holdings

Net buy/sell shares 10,803 shares net sold Net change in common stock holdings in this filing

Key Terms

Rule 10b5-1 trading plan, restricted stock units, performance stock units

3 terms

Rule 10b5-1 trading plan regulatory

"transactions were made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"shares of common stock issuable pursuant to previously reported restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance stock units financial

"issuable pursuant to previously reported restricted stock units and earned performance stock units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INCYTE CORP (INCY) disclose for Pablo J. Cagnoni?

INCYTE CORP disclosed that Pablo J. Cagnoni, President and Global Head of R&D, sold 10,803 shares of common stock. The sale occurred on 2026-08-12 as an open-market transaction at $120.04 per share, reported as a planned trade under Rule 10b5-1.

At what price were the INCY shares sold in the latest Form 4 filing?

The reported transaction shows shares sold at an average price of $120.04 per share. This price applies to the 10,803 shares of INCYTE CORP common stock sold on 2026-08-12 in an open-market or private transaction, as characterized in the filing.

How many INCYTE CORP (INCY) shares does Pablo J. Cagnoni hold after the reported sale?

After the reported sale, Pablo J. Cagnoni is shown holding 194,001 shares of INCYTE CORP common stock directly. This figure includes 183,200 shares issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.

Was the INCYTE CORP (INCY) insider sale made under a Rule 10b5-1 plan?

Yes, the filing indicates the transactions were made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is marked, signaling that this insider sale was executed pursuant to a pre-arranged trading plan rather than a discretionary trade.

What portion of Pablo J. Cagnoni’s reported INCY holdings relates to unvested equity awards?

Out of the reported 194,001 shares following the transaction, 183,200 shares are tied to unvested restricted stock units and earned performance stock units. These shares are issuable in the future, subject to vesting of the underlying equity awards previously reported.

What role does Pablo J. Cagnoni hold at INCYTE CORP (INCY) in this Form 4?

In this Form 4, Pablo J. Cagnoni is identified as President, Global Head of R&D at INCYTE CORP. The reported transaction covers his personal direct holdings of common stock, as distinguished from any indirect or entity-level ownership interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:03 PM Accepted by SEC EDGAR 08/14/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAGNONI PABLO J

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DELAWARE 19803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Global Head of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		S		10,803	D	$120.04	194,001(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)